COMBAT-MS is a research project financed by PCORI

Rituximab in multiple sclerosis: A comparative study on effectiveness, safety, and patient reported outcomes

PI: Fredrik Piehl, MS neurologist, professor
Karolinska University Hospital and Karolinska Institutet
Stockholm Sweden

Photo: N/A

The objectives of COMBAT-MS is to compare rituximab (RTX) and other disease-modifying treatments (DMTs) regarding efficacy, safety, tolerability, and patient satisfaction.

We will study:

  1. How RTX compare with other DMTs in patients who have had continued disease activity on a previous DMT
  2. How does RTX compare with other DMTs in patients faced with choosing their first MS medication
Ann Hagerborn